Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Compugen Ltd. (NASDAQ: CGEN).

Full DD Report for CGEN

You must become a subscriber to view this report.


Recent News from (NASDAQ: CGEN)

Compugen's (CGEN) CEO Anat Cohen-Dayag on Q1 2018 Results - Earnings Call Transcript
Compugen Ltd. (CGEN) Q1 2018 Earnings Conference Call May 9, 2018 10:00 AM ET Executives Elana Holzman – Director, IR and Corporate Communications Anat Cohen-Dayag – President and Chief Executive Officer Ari Krashin – Chief Financial Officer and Chief Operati...
Source: SeekingAlpha
Date: May, 09 2018 14:07
Compugen up 2% on Q1 result
Compugen ( CGEN ) Q1 results : Revenues: $10M; Net Income: $0.1M (+101.1%); EPS: $0.00; Quick Assets: $20.5M (-32.6%). More news on: Compugen Ltd., Healthcare stocks news, Earnings news and commentary, , Read more ...
Source: SeekingAlpha
Date: May, 09 2018 09:03
Compugen beats by $0.19, beats on revenue
Compugen (NASDAQ: CGEN ): Q1 EPS of $0.00 beats by $0.19 . More news on: Compugen Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: May, 09 2018 07:04
Compugen Reports First Quarter 2018 Results
HOLON, Israel , May 9, 2018 /PRNewswire/ --  Compugen Ltd.  (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial results for the first quarter ended March 31, 2018 . "Key developments in the firs...
Source: PR Newswire
Date: May, 09 2018 07:00
Compugen First Quarter 2018 Conference Call Scheduled for Wednesday, May 9, 2018 at 10:00 AM ET
HOLON, Israel , April 30, 2018 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, announced today that the Company will release its first quarter 2018 financial results on Wednesday, ...
Source: PR Newswire
Date: April, 30 2018 07:00
Compugen not quite there with COM701 IND; shares down 7%
Thinly traded micro cap Compugen ( CGEN -7.1% ) slips on average volume on the heels of its announcement that the FDA has requested additional CMC (Chemistry, Manufacturing and Controls) information to support its IND application for cancer candidate COM701. More news on: Compugen Ltd....
Source: SeekingAlpha
Date: April, 27 2018 11:54
Blog Exposure - Preclinical Data Presented by Bayer at AACR Highlights Compugen's BAY 1905254 Efficacy in Cancer Immunotherapy
Stock Monitor: Affimed Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 19, 2018 / Active-Investors.com has just released a free research report on Compugen Ltd (NASDAQ: CGEN ). If you want access to this report all you need to do is sign up now by clicking the following link ...
Source: ACCESSWIRE IA
Date: April, 19 2018 07:40
Bayer's ILDR2 inhibitor shows encouraging action in preclinical studies, discoverer Compugen up 4%
Compugen Ltd. ( CGEN +3.5% ) is up in early trade on light volume on the heels of its announcement that licensee Bayer AG ( OTCPK:BAYRY +0.3% ) presented encouraging preclinical data on BAY 1905254 at the American Association of Cancer Research Annual Meeting in Chicago. More news on...
Source: SeekingAlpha
Date: April, 17 2018 09:49
Preclinical Data Presented by Bayer at AACR Highlights BAY 1905254, Formerly the CGEN-15001T Program, Efficacy in Cancer Immunotherapy
HOLON, Israel , April 17, 2018 /PRNewswire/ --  Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that preclinical data presented by Bayer AG at the Annual Meeting of the American ...
Source: PR Newswire
Date: April, 17 2018 07:00
Compugen's (CGEN) CEO Anat Cohen-Dayag on MedImmune License Agreement Call (Transcript)
Compugen Ltd. (CGEN) MedImmune License Agreement April 02, 2018 08:30 AM ET Executives Elana Holzman - Director, IR and Corporate Communications Anat Cohen-Dayag - President and CEO Ari Krashin - CFO and COO Kirk Christoffersen - SVP, Business Development Analysts Mike Ki...
Source: SeekingAlpha
Date: April, 05 2018 14:03

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-183.303.253.453.25270,528
2018-05-173.303.253.453.25270,528
2017-02-024.654.654.704.6531,790
2017-02-014.754.704.854.6550,165
2017-01-314.604.754.804.6057,241

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1643,98574,44559.0839Short
2018-08-1547,99272,57466.1284Short
2018-08-1425,86933,76076.6262Short
2018-08-138,95114,53361.5909Short
2018-08-1018,31023,90176.6077Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CGEN.


About Compugen Ltd. (NASDAQ: CGEN)

Logo for Compugen Ltd. (NASDAQ: CGEN)

Not available

 

Contact Information

 

 

Current Management

  • Alex Kotzer / President, CEO

Current Share Structure

  • Market Cap: $171,831,785 - 05/11/2018
  • Issue and Outstanding: 51,293,070 - 12/31/2017

 


Recent Filings from (NASDAQ: CGEN)

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 09 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 27 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 02 2018
Annual and transition report of foreign private issuers under sections 13 or 15(d)
Filing Type: 20-FFiling Source: edgar
Filing Date: March, 27 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: March, 27 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: March, 14 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: February, 21 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: February, 06 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: January, 31 2018

 

 


Daily Technical Chart for (NASDAQ: CGEN)

Daily Technical Chart for (NASDAQ: CGEN)


Stay tuned for daily updates and more on (NASDAQ: CGEN)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: CGEN)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CGEN is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of CGEN and does not buy, sell, or trade any shares of CGEN. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/